Table 4 Percent changes (95% confidence interval) in outcome levels, according to exposure scenario comparing active to sham filtration estimated by mixed-effects models adjusted for BMI, age and gender

MVF

−1.4 (−9.1, 7.0)

−5.2 (−12.5, 2.7)

2.8 (−5.6, 12.0)

−1.4 (−5.8, 3.2)

C-reactive protein

3.7 (−15.3, 26.9)

−11.3 (−29.1,10.9)

−3.6 (−24.9, 23.8)

−4.5 (−15.5, 7.9)

Hemoglobin

−2.2 (−5.7, 1.4)

−2.1 (−5.5, 1.3)

−5.2 (−14.7, 5.3)

−3.2 (−6.9, 0.7)

Leukocytes

−0.7 (−6.6, 5.6)

−0.7 (−6.0, 5.0)

2.4 (−3.1, 8.3)

0.2 (−3.1, 3.6)

Lymphocytes

3 (−3.7, 10.1)

−0.6 (−7.5, 6.9)

3.4 (−5.1, 12.6)

1.7 (−2.4, 6.1)

Monocytes

−0.4 (−5.8, 6.1)

−1.5 (−7.1, 4.3)

2.2 (−4.5, 9.4)

0.05 (−3.3, 3.5)

Granulocytes

−3.8 (−12.4, 5.6)

0.5 (−7.9, 9.7)

2.4 (−5.9, 11.6)

−0.4 (−5.3, 4.7)

CD31

−0.01 (−1.4, 1.4)

−3.7 (−9.1, 2.1)

1.3 (−1.7, 4.4)

−0.8 (−3.1, 1.5)

CD62L

−4.4*(−8.4, -0.2)

−2.9 (−10.7, 5.6)

6.1 (−0.3, 12.9)

−0.4 (−4.2, 3.7)

CD11b

10.4 (−9.1, 34.3)

−6.2 (−19.3, 9.0)

−11.4 (−26.2, 6.4)

−3.1 (−12.5, 7.4)

CD49d

1.3 (−11.8, 16.4)

−2.2 (−9.1, 5.3)

−2.9 (−11.5, 6.5)

−1.3 (−6.9, 4.7)

FEV₁/FVC

0.16 (−12.1, 14.1)

5.1 (−5.4, 16.8)

−2.2 (−9.2, 5.4)

0.8 (−5.1, 7.1)

CC16

−0.4 (−10.1, 10.3)

−1 (−13.4, 13.3)

0.2 (−8.8, 10.2)

−0.3 (−6.4, 6.1)

SPD

−0.2 (−7.3, 7.4)

−2 (−8.1, 4.5)

5.1 (−1.7, 12.5)

0.9 (−2.8, 4.7)